| Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer's disease: the NF-κB connection U Kaur, P Banerjee, A Bir, M Sinha, A Biswas, S Chakrabarti Current topics in medicinal chemistry 15 (5), 446-457, 2015 | 134 | 2015 |
| Oxidative stress, neuroinflammation, and NADPH oxidase: implications in the pathogenesis and treatment of Alzheimer’s disease U Ganguly, U Kaur, SS Chakrabarti, P Sharma, BK Agrawal, L Saso, ... Oxidative Medicine and Cellular Longevity 2021 (1), 7086512, 2021 | 97 | 2021 |
| A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers-first results from India U Kaur, B Ojha, BK Pathak, A Singh, KR Giri, A Singh, A Das, A Misra, ... EClinicalMedicine 38, 2021 | 88 | 2021 |
| Esketamine: a glimmer of hope in treatment-resistant depression U Kaur, BK Pathak, A Singh, SS Chakrabarti European archives of psychiatry and clinical neuroscience 271, 417-429, 2021 | 70 | 2021 |
| Alpha-synuclein, proteotoxicity and Parkinson's disease: search for neuroprotective therapy U Ganguly, SS Chakrabarti, U Kaur, A Mukherjee, S Chakrabarti Current neuropharmacology 16 (7), 1086-1097, 2018 | 62 | 2018 |
| COVID-19 in India: are biological and environmental factors helping to stem the incidence and severity? SS Chakrabarti, U Kaur, A Banerjee, U Ganguly, T Banerjee, S Saha, ... Aging and disease 11 (3), 480, 2020 | 61 | 2020 |
| Targeting host cell proteases to prevent SARS-CoV-2 invasion U Kaur, SS Chakrabarti, B Ojha, BK Pathak, A Singh, L Saso, ... Current Drug Targets 22 (2), 192-201, 2021 | 48 | 2021 |
| Occurrence of COVID‐19 in priority groups receiving ChAdOx1 nCoV‐19 coronavirus vaccine (recombinant): a preliminary analysis from north India U Kaur, S Bala, B Ojha, S Jaiswal, S Kansal, SS Chakrabarti Journal of medical virology 94 (1), 407-412, 2022 | 38 | 2022 |
| Interaction of α-synuclein and Parkin in iron toxicity on SH-SY5Y cells: implications in the pathogenesis of Parkinson's disease U Ganguly, A Banerjee, SS Chakrabarti, U Kaur, O Sen, R Cappai, ... Biochemical Journal 477 (6), 1109-1122, 2020 | 36 | 2020 |
| Antiepileptic drug therapy in the elderly: a clinical pharmacological review U Kaur, I Chauhan, IS Gambhir, SS Chakrabarti Acta Neurologica Belgica 119, 163-173, 2019 | 36 | 2019 |
| Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2 U Kaur, K Acharya, R Mondal, A Singh, L Saso, S Chakrabarti, ... European journal of pharmacology 887, 173545, 2020 | 33 | 2020 |
| Rapidly progressive dementia with asymmetric rigidity following ChAdOx1 nCoV-19 vaccination SS Chakrabarti, A Tiwari, S Jaiswal, U Kaur, I Kumar, A Mittal, A Singh, ... Aging and disease 13 (3), 633, 2022 | 26 | 2022 |
| Of cross-immunity, herd immunity and country-specific plans: Experiences from COVID-19 in India SS Chakrabarti, U Kaur, A Singh, S Chakrabarti, M Krishnatreya, ... Aging and disease 11 (6), 1339, 2020 | 24 | 2020 |
| Zoledronate induced hypocalcemia and hypophosphatemia in osteoporosis: a cause of concern U Kaur, S Shubhra Chakrabarti, I Singh Gambhir Current drug safety 11 (3), 267-269, 2016 | 24 | 2016 |
| Persistent health issues, adverse events, and effectiveness of vaccines during the second wave of COVID-19: a cohort study from a tertiary hospital in North India U Kaur, S Bala, A Joshi, NTS Reddy, C Japur, M Chauhan, N Pedapanga, ... Vaccines 10 (7), 1153, 2022 | 23 | 2022 |
| Acute cardiac events after ChAdOx1 nCoV-19 corona virus vaccine: report of three cases R Singh, SS Chakrabarti, IS Gambhir, A Verma, I Kumar, S Ghosh, ... American Journal of Therapeutics 29 (5), e579-e585, 2022 | 19* | 2022 |
| Long-term safety analysis of the ChAdOx1-nCoV-19 corona virus vaccine: results from a prospective observational study in priority vaccinated groups in North India U Kaur, Z Fatima, K Maheshwari, V Sahni, A Dehade, A Kl, AK Yadav, ... Drug safety 46 (6), 553-563, 2023 | 18 | 2023 |
| Multi-target directed ligands (MTDLs): promising coumarin hybrids for Alzheimer’s disease R Bhatia, SS Chakrabarti, U Kaur, G Parashar, A Banerjee, RK Rawal Current Alzheimer Research 18 (10), 802-830, 2021 | 18 | 2021 |
| Lecanemab: more questions than answers! U Kaur, J Reddy, A Tiwari, S Chakrabarti, SS Chakrabarti Clinical Drug Investigation 44 (1), 1-10, 2024 | 17 | 2024 |
| Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis U Kaur, SS Chakrabarti, TK Patel Therapeutic advances in drug safety 12, 20420986211011345, 2021 | 16 | 2021 |
